marketcaparena

XORTX Therapeutics Inc.

XRTX

About XORTX Therapeutics

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

xortx.com ↗

Employees
0
Listed
Nasdaq · XRTX

Income statement

Revenue, gross profit and net income

Q1 26
Full year
Quarter
Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.

Cash flow

Operating and free cash flow

Q1 26
Full year
Quarter
Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.

Stock-based compensation

Q1 26
Full year
Quarter
Stock-based compensation reported in the cash flow statement each period. The line is that amount as a percentage of the same period's revenue.
Stock-based compensation